Achieve Life Sciences adds ex-Verona Pharma CCO Christopher Martin to board
Merck & Co., Inc.
Achieve Life Sciences, Inc.
Merck & Co., Inc. MRK | 0.00 | |
Achieve Life Sciences, Inc. ACHV | 0.00 |
- Achieve Life Sciences named Christopher Martin to board of directors, adding former Verona Pharma chief commercial officer who led commercial strategy for COPD therapy Ohtuvayre (ensifentrine).
- Mark Zappia joined as senior vice president, commercial; he previously led commercial operations for Ohtuvayre launch at Verona Pharma.
- Jim Willis joined as vice president of sales and sales enablement; he previously led Verona Pharma national field force during Ohtuvayre launch.
- Board change set for June 2026, with Tom King stepping down; Lucian Iancovici to become chairman.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120705PRIMZONEFULLFEED9718117) on May 12, 2026, and is solely responsible for the information contained therein.
